Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders
- 5 November 2020
- journal article
- editorial
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 30 (1) , 1-4
Abstract
Copper serves as a structural and catalytic cofactor for a variety of enzymes in aerobic organisms. Though present in trace amounts, copper is essential for numerous biochemical processes including...Keywords
Funding Information
- National Institutes of Health (R01GM111672)
- The Welch Foundation (A-1810)
This publication has 24 references indexed in Scilit:
- Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced MelanomaJournal of Clinical Oncology, 2013
- Inborn errors of copper metabolism2013
- The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cellsFree Radical Biology and Medicine, 2012
- ATP7A-related copper transport diseases—emerging concepts and future trendsNature Reviews Neurology, 2011
- Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic MelanomaJournal of Clinical Oncology, 2009
- Menkes diseaseEuropean Journal of Human Genetics, 2009
- Elesclomol induces cancer cell apoptosis through oxidative stressMolecular Cancer Therapeutics, 2008
- Mechanisms for copper acquisition, distribution and regulationNature Chemical Biology, 2008
- Neonatal Diagnosis and Treatment of Menkes DiseaseNew England Journal of Medicine, 2008
- Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid TumorsClinical Cancer Research, 2007